DK0832098T3 - Fremgangsmåde til fremstilling af IGF-I og IGFBP-3 med korrekt foldning og korrekte disulfidbindinger - Google Patents

Fremgangsmåde til fremstilling af IGF-I og IGFBP-3 med korrekt foldning og korrekte disulfidbindinger

Info

Publication number
DK0832098T3
DK0832098T3 DK96916829T DK96916829T DK0832098T3 DK 0832098 T3 DK0832098 T3 DK 0832098T3 DK 96916829 T DK96916829 T DK 96916829T DK 96916829 T DK96916829 T DK 96916829T DK 0832098 T3 DK0832098 T3 DK 0832098T3
Authority
DK
Denmark
Prior art keywords
igfbp
igf
correct
disulfide bonds
folding
Prior art date
Application number
DK96916829T
Other languages
English (en)
Inventor
Yasushi Ogawa
Andreas Sommer
Peggy Tao
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of DK0832098T3 publication Critical patent/DK0832098T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK96916829T 1995-06-07 1996-05-30 Fremgangsmåde til fremstilling af IGF-I og IGFBP-3 med korrekt foldning og korrekte disulfidbindinger DK0832098T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/482,271 US5789547A (en) 1995-06-07 1995-06-07 Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
PCT/US1996/008113 WO1996040736A1 (en) 1995-06-07 1996-05-30 Method of producing igf-i and igfbp-3 with correct folding and disulfide bonding

Publications (1)

Publication Number Publication Date
DK0832098T3 true DK0832098T3 (da) 2002-12-16

Family

ID=23915418

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916829T DK0832098T3 (da) 1995-06-07 1996-05-30 Fremgangsmåde til fremstilling af IGF-I og IGFBP-3 med korrekt foldning og korrekte disulfidbindinger

Country Status (15)

Country Link
US (1) US5789547A (da)
EP (1) EP0832098B1 (da)
JP (1) JPH11507037A (da)
KR (1) KR19990022718A (da)
CN (1) CN1214689A (da)
AT (1) ATE223926T1 (da)
AU (1) AU703489B2 (da)
CA (1) CA2223495A1 (da)
CZ (1) CZ394397A3 (da)
DE (1) DE69623620T2 (da)
DK (1) DK0832098T3 (da)
ES (1) ES2179943T3 (da)
NO (1) NO975749L (da)
PL (1) PL323731A1 (da)
WO (1) WO1996040736A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5914390A (en) * 1997-05-12 1999-06-22 Celtrix Pharmaceuticals, Inc. Methods for increasing yields of recombinant proteins
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
WO2001075095A1 (fr) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Procede de production de proteine de recombinaison
US20050033035A1 (en) * 2001-06-07 2005-02-10 Hans-Georg Beisel Mutants of igf binding proteins and methods of production of antagonists thereof
CA2899824A1 (en) * 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
WO2008130315A1 (en) 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
CN104011070A (zh) * 2011-12-15 2014-08-27 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
CN107991492A (zh) * 2017-11-17 2018-05-04 广州赛莱拉干细胞科技股份有限公司 一种胰岛素样生长因子结合蛋白-3的定量检测试剂盒及其非诊断目的的检测方法
CN111876490B (zh) * 2020-07-03 2022-07-15 扬州大学 一种提高猪生长速度的连锁分子标记、其检测方法及应用
KR20230113287A (ko) 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
US20250099541A1 (en) 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU3812993A (en) * 1992-03-24 1993-10-21 Synergen, Inc. Refolding and purification of insulin-like growth factor I
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf

Also Published As

Publication number Publication date
NO975749D0 (no) 1997-12-05
US5789547A (en) 1998-08-04
WO1996040736A1 (en) 1996-12-19
CN1214689A (zh) 1999-04-21
ATE223926T1 (de) 2002-09-15
PL323731A1 (en) 1998-04-14
ES2179943T3 (es) 2003-02-01
KR19990022718A (ko) 1999-03-25
AU703489B2 (en) 1999-03-25
DE69623620D1 (de) 2002-10-17
AU5957696A (en) 1996-12-30
DE69623620T2 (de) 2003-08-07
NO975749L (no) 1998-01-27
EP0832098A4 (en) 1999-09-15
JPH11507037A (ja) 1999-06-22
CZ394397A3 (cs) 1998-09-16
EP0832098A1 (en) 1998-04-01
CA2223495A1 (en) 1996-12-19
EP0832098B1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
NO975749D0 (no) Fremgangsmåte for fremstilling av IGF-1 og IGFBP-3 med korrekt folding og disulfid binding
ATE278703T1 (de) Verfahren zur herstellung von konjugat- impfstoffen unter verwendung von uroniumsalz
ES2058341T3 (es) Subunidades de proteina portadoras de somatomedina humana y proceso para producirlas.
NO975729D0 (no) Forbindelser og peptider som binder til etytropoietinreseptoren
DE59305396D1 (de) Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
DE3855536D1 (de) Rezeptoren für wachstumshormone
DE68918556D1 (de) Bindeproteine für insulinähnliche Wachstumsfaktoren.
ZA899832B (en) Human somatomedin carrier protein subunits and process for producing them;recombinant dna molecules,hosts,processes and human somatomedian carrier protein-like polypeptides
DK16196A (da) Fremgangsmåde til fremstilling af glycosphingolipider
ATE207934T1 (de) Neues verfahren für die produktion von biologisch aktivem protein (tgf)
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
FI93842B (fi) Menetelmä proteiinien renaturoimiseksi
EP0726944A4 (en) GLYCOSYLATED AND NON-GLYCOSYLATED PROTEINS, BACTERICIDES AND INCREASING PERMEABILITY, AND PROCESS FOR PRODUCING THE SAME
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
EP0208539A3 (en) Folding disulfide-cross-linkable proteins
DE69609054D1 (de) Ein prozess für die herstellung von faktor ix biologischen ursprungs
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
GR3025246T3 (en) METHOD FOR PREPARING A PROTEIN SELECTED FROM THE CYTOKINE GROUP, COMPRISING AT LEAST ONE INTRAMOLECULAR DISULPHIDE BOND BY OXIDATION, AT A pH OF LESS THAN 5.0, OF THE REDUCED RECOMBINANT PROTEIN
NO995427L (no) Humanprohormonkonvertase 4
DE59702919D1 (de) Verfahren zur Herstellung von N-(2-Carboxy-5-chlor-phenyl)glycin
ATE183994T1 (de) Verfahren zur herstellung n-z-geschützter n- alkylierter aminosäuren
ATE245146T1 (de) Verfahren zur herstellung von ar(alk)yluracilen, neue zwischenprodukte hierfür und verfahren zu deren herstellung
ATE193284T1 (de) Verfahren zur herstellung von benzylsubstituierten rhodaninederivaten